Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
setrusumab
- Development stage
- Phase 3
- Lead developer
- Ultragenyx Pharmaceutical
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
Setrusumab is a fully human monoclonal antibody developed to inhibit sclerostin, a negative regulator of bone formation. By blocking sclerostin (SOST protein), setrusumab increases new bone formation, bone mineral density (BMD), and bone strength. Its primary indication is for the treatment of osteogenesis imperfecta (OI), where it has demonstrated significant reductions in fracture rates and improvements in BMD in clinical trials. Setrusumab has received orphan drug status and Breakthrough Therapy designation for OI. The drug was originally developed by MorphoSys and Novartis and is being further developed by Mereo BioPharma and Ultragenyx Pharmaceutical[1][2][3][4][5][6][7][8].
- Other names
- Anti-sclerostin-monoclonal-antibody-Mereo
02
Targets
SOST (Sclerostin)
Beyond the preview
Go deeper on setrusumab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on setrusumab.